Revenue Interest Assignment Agreement Sample Contracts
ContractRevenue Interest Assignment Agreement • May 5th, 2020 • New York
EX-10.3 3 pdl-2016063010qex103.htm AMENDMENT NO. 1 TO RIAA Exhibit 10.3 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* * *” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. AMENDMENT NO. 1 TO RIAA This AMENDMENT NO. 1 TO RIAA (this “Amendment”) is made and entered into as of May 9, 2016 by and between ARIAD Pharmaceuticals, Inc., a Delaware corporation (“ARIAD” or the “Company”), and PDL BioPharma, Inc., a Delaware corporation (“Purchaser”), each party to that certain Revenue Interest Assignment Agreement, dated as of July 28, 2015 (as amended, restated, amended and restated, modified and/or supplemented from time to time, the “RIAA”). Capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the RIAA. WHEREAS, the Company and Purchaser are contemporaneously entering into that certain Waiver and
ContractRevenue Interest Assignment Agreement • May 5th, 2020 • New York
EX-10.3 4 pdli-201593010qex103.htm REVENUE INTEREST ASSIGNMENT AGREEMENT Exhibit 10.3 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* * *” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. REVENUE INTEREST ASSIGNMENT AGREEMENT Dated as of July 28, 2015 between ARIAD PHARMACEUTICALS, INC. and PDL BIOPHARMA, INC. Table of Contents
July 20, 2005 CONFIDENTIALRevenue Interest Assignment Agreement • July 22nd, 2005 • Guilford Pharmaceuticals Inc • Pharmaceutical preparations
Paul Royalty Fund, L.P. Paul Royalty Fund Holdings II c/o Paul Capital Management, L.L.C. 50 California Street Suite 3000 San Francisco, CA 94111 Attention: Chief Financial Officer
AMENDMENT NO. 1 TO RIAARevenue Interest Assignment Agreement • August 8th, 2016 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This AMENDMENT NO. 1 TO RIAA (this “Amendment”) is made and entered into as of May 9, 2016 by and between ARIAD Pharmaceuticals, Inc., a Delaware corporation (“ARIAD” or the “Company”), and PDL BioPharma, Inc., a Delaware corporation (“Purchaser”), each party to that certain Revenue Interest Assignment Agreement, dated as of July 28, 2015 (as amended, restated, amended and restated, modified and/or supplemented from time to time, the “RIAA”). Capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the RIAA.
REVENUE INTEREST ASSIGNMENT AGREEMENT Dated as of July 28, 2015 between ARIAD PHARMACEUTICALS, INC. and PDL BIOPHARMA, INC. Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and...Revenue Interest Assignment Agreement • November 6th, 2015 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This REVENUE INTEREST ASSIGNMENT AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of July 28, 2015, by and between ARIAD Pharmaceuticals, Inc., a Delaware corporation (“ARIAD” or the “Company”), and PDL BioPharma, Inc., a Delaware corporation (“Purchaser”).
EXHIBIT 2.04 REVENUE INTEREST ASSIGNMENT AGREEMENT Dated as of October 28, 2003Revenue Interest Assignment Agreement • November 12th, 2003 • Guilford Pharmaceuticals Inc • Pharmaceutical preparations • New York
CONFIDENTIALRevenue Interest Assignment Agreement • July 22nd, 2005 • Mgi Pharma Inc • Pharmaceutical preparations